The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Enhancement of cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) with lenalidomide in advanced solid tumors: A phase 1 trial.
Erin Marie Bertino
No relevant relationships to disclose
Elizabeth L McMichael
No relevant relationships to disclose
Miguel Angel Villalona-Calero
No relevant relationships to disclose
Michael R. Grever
No relevant relationships to disclose
William Edgar Carson
No relevant relationships to disclose
Gregory Alan Otterson
Research Funding - NCCN - Abraxis now Celgene